A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN). (SIRIUS-LN)

  • End date
    Jul 15, 2030
  • participants needed
  • sponsor
    Novartis Pharmaceuticals
Updated on 22 October 2022
induction therapy
systemic lupus erythematosus


This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN


This trial will evaluate the efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or ianalumab given every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN (ISN/RPS class III, IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous). using the 2003 International Society for Nephrology (ISN)/Renal Pathology Society (RPS) criteria).

Condition Lupus Nephritis
Treatment ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.
Clinical Study IdentifierNCT05126277
SponsorNovartis Pharmaceuticals
Last Modified on22 October 2022


Yes No Not Sure

Inclusion Criteria

Participants eligible for inclusion in this study must meet all of the
following criteria
Adult male and female participants aged 18 years or older at the time of
Weigh at least 35 kg at screening
Have a confirmed clinical diagnosis of SLE according to European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) Systemic lupus erythematosus (SLE)
classification criteria
Have a positive anti-nuclear antibody (ANA) test result; ANA titer ≥1:80 at screening visit
based on central laboratory result
Active LN at screening, as defined by meeting the 3 following criteria
Biopsy within 6 months prior to screening period indicating ISN/RPS class III or IV
active glomerulonephritis with or without co-existing class V features, or pure class
V membranous LN. If no biopsy was performed within 6 months prior to screening period
a biopsy will need to be performed during the screening period after having met all
UPCR ≥1.0 on 24h urine collection at Screening
eGFR ≥25mL/min/1.73 m2
Participants must be currently on, or willing to initiate SoC induction therapy for LN
according to the institutional practices using MPA
Receipt of at least one dose of pulse methylprednisolone i.v. (500-1000 mg) or equivalent
for treatment of current episode of active LN during past 60 days prior screening
Able to communicate well with the Investigator to understand and comply with the
requirements of the study

Exclusion Criteria

Participants meeting any of the following criteria are not eligible for inclusion in this
Severe renal impairment as defined by i.) Stage 4 Chronic Kidney Disease (CKD), or ii.)
presence of oliguria (defined as a documented urine volume <400 mL/24 hrs), or iii.)
End-Stage Renal Disease (ESRD) requiring dialysis or transplantation
Sclerosis in >50% of glomeruli on renal biopsy
Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or
until the expected pharmacodynamic effect has returned to baseline
Prior use of any B cell depleting therapy within 36 weeks prior to randomization or as long
as B cell count <50 cells/μL
Prior treatment with any of the following within 12 weeks prior to randomization
belimumab, abatacept, TNF-α mAb, immunoglobulins (i.v./s.c.) plasmapheresis
any other immuno-suppressants (i.v. or oral cyclophosphamide, calcineurin inhibitors
JAK inhibitors or other kinase inhibitors)
thalidomide treatment and/or one of the following DMARDs: methotrexate or an imidazole
derivative (e.g., azathioprine, mizoribine)
Receipt of more than 3000 mg i.v. pulse methylprednisolone (cumulative dose) within 12
weeks prior to Baseline
History of major organ transplant or hematopoietic stem cell/bone marrow transplant or are
due to receive transplantation
Any one of the following laboratory values at screening
Hemoglobin levels <8.0 g/dL
Platelet count <75 x 1000/µL
Absolute neutrophil count (ANC) <1.0 x 1000/µL
Active viral, bacterial or other infections requiring systemic treatment at the time of
screening, or history of recurrent clinically significant infection or of bacterial
infections with encapsulated organisms
History of known intolerance/hypersensitivity to MPA, oral corticosteroids, or any
component of the study drug(s) or its excipients
Receipt of live/attenuated vaccine within a 4-week period prior to randomization
History of primary or secondary immunodeficiency, including a positive HIV test result
History of malignancy of any organ system (other than localized basal cell carcinoma or
squamous cell carcinoma of the skin or or in-situ cervical cancer), treated or untreated
within the past 5 years, regardless of whether there is evidence of local recurrence or
Any surgical, medical (e.g., uncontrolled hypertension, heart failure or diabetes)
psychiatric or additional physical condition that the Investigator feels may jeopardize the
patient in case of participation in this study
Chronic infection with hepatitis B (HBV) or hepatitis C (HCV). Positive serology for
hepatitis B surface antigen (HBsAg) excludes the participant
Evidence of active tuberculosis (TB) infection (after anti-TB treatment, participants with
history of TB may become eligible according to national guidelines)
Pregnant or nursing (lactating) women
Women of child-bearing potential, defined as all women physiologically capable of becoming
pregnant, unless they are using highly effective methods of contraception during dosing and
for 6 months after stopping of investigational medication
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note